Please ensure Javascript is enabled for purposes of website accessibility

Pfizer, Merck, and Others See a Slowdown in Vaccine Sales, but Anticipate an Autumn Rebound

By Eric Volkman – Updated Aug 6, 2020 at 2:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Many people are putting off vaccinations for diseases they view as less threatening than the coronavirus.

With all the news and chatter about coronavirus vaccine candidates these days, it might be somewhat surprising to learn that sales of established vaccines have been dropping lately.

Biopharma Dive reported that the world's top four vaccine makers -- pharmaceutical giants Pfizer (PFE 0.73%), Merck (MRK 0.88%), Sanofi (SNY 0.33%) and GlaxoSmithKline (GSK -0.68%) -- have all experienced notable volume declines in the category.

Sanofi's vaccine sales fell 7% on a year-over-year basis in its most recently reported quarter. Its European peer GlaxoSmithKline suffered sales drops in all components of its vaccines unit, with sales of one of its top products (Shingrix, aimed at preventing shingles) sliding by 16% -- its steepest decline ever.

A syringe being filled with a vaccine from a vial.

Image source: Getty Images.

The primary reason for this is, of course, the coronavirus pandemic. While the health crisis has heightened public awareness of the need for effective vaccines, the shelter-in-place measures it has engendered have kept many people out of doctors' offices. Additionally, many people might not consider getting vaccinated for those long-established illnesses as urgently necessary right now.

The immediate future doesn't look rosy for the vaccine segment, as local coronavirus outbreaks have intensified rapidly in a majority of U.S. states over the past two months, with the rates of daily new diagnoses reaching peaks many times higher than they were in April, when the country's early hot spots had their worst days. Even if renewed efforts to reduce transmission do bring those new case numbers back down before the end of this year, many people will likely continue to avoid social contact situations such as doctor visits when they can.

However, some of the affected companies sounded hopeful notes, and a few believe that a turnaround will come soon. "We expect to see vaccination rates recover in the second half of the year," said GlaxoSmithKline's CEO Emma Walmsley.

Meanwhile, Thomas Triomphe, Sanofi's head of vaccines, spoke of his company's "readiness for a record flu season," as it is seeing high preseason demand for this year's version of its influenza vaccine.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co. Stock Quote
Merck & Co.
$108.45 (0.88%) $0.95
Pfizer Stock Quote
$49.57 (0.73%) $0.36
Sanofi Stock Quote
$45.54 (0.33%) $0.15
GSK plc Stock Quote
GSK plc
$33.76 (-0.68%) $0.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.